Sunshine Nuohe's wholly-owned subsidiary, Chengdu Nuohe Shengtai Biotechnology, has received clinical trial approval from the National Medical Products Administration for its Class 1 innovative drug STC009 injection. The drug is intended for the treatment of secondary hyperparathyroidism. It is a calcium-sensing receptor peptide agonist developed using the company's proprietary iCVETide peptide drug discovery platform, and related research findings have been published in the top international journal Journal of Medicinal Chemistry. In the first quarter of 2026, Sunshine Nuohe achieved revenue of 197 million yuan and a net profit attributable to the parent company of 20.63 million yuan.
Beijing Sun Novo Pharmaceutical Research Co LtdSubsidiary's STC009 injection received clinical trial approval, a positive drug development milestone.
Wholly-owned subsidiary received clinical trial approval for its Class 1 innovative drug STC009.